NASDAQ:BRKR - Bruker Stock Price, Price Target & More

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker declared a quarterly dividend on Tuesday, May 15th. Shareholders of record on Monday, June 4th will be given a dividend of $0.04 per share on Friday, June 22nd. This represents a $0.16 annualized dividend and a yield of 0.53%. The ex-dividend date is Friday, June 1st. View Bruker's Dividend History.

Bruker declared that its Board of Directors has authorized a stock buyback plan on Sunday, June 4th 2017, which authorizes the company to buyback $225,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

Bruker Co. (NASDAQ:BRKR) issued its earnings results on Thursday, May, 3rd. The medical research company reported $0.24 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.22 by $0.02. The medical research company earned $431.70 million during the quarter, compared to the consensus estimate of $419.25 million. Bruker had a return on equity of 27.04% and a net margin of 4.63%. The business's revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.19 EPS. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Bruker.

9 Wall Street analysts have issued 1-year price objectives for Bruker's shares. Their predictions range from $24.00 to $42.00. On average, they anticipate Bruker's share price to reach $32.8889 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Ratings for Bruker.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Bruker include Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), PerkinElmer (PKI), Bio-Rad Laboratories, Inc. Class B (BIO.B), Integra Lifesciences (IART), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT) and HTG Molecular Diagnostics (HTGM).

News headlines about BRKR stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bruker earned a coverage optimism score of 0.07 on Accern's scale. They also gave media stories about the medical research company an impact score of 45.93 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Bruker's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.12%), Cambiar Investors LLC (0.10%), Thompson Rubinstein Investment Management Inc. OR (0.09%), Fisher Asset Management LLC (0.09%), Clinton Group Inc. (0.03%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch, Richard A Packer and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Fisher Asset Management LLC and Scout Investments Inc.. View Insider Buying and Selling for Bruker.

BRKR stock was bought by a variety of institutional investors in the last quarter, including Clinton Group Inc., Cornerstone Wealth Management LLC, Fox Run Management L.L.C., Thompson Rubinstein Investment Management Inc. OR and State of Alaska Department of Revenue. Company insiders that have bought Bruker stock in the last two years include Frank H Laukien and Richard A Packer. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $30.19.

Bruker has a market capitalization of $4.71 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]